Carna Biosciences, Inc.
Notice on Monthly Exercise Status of Docirbrutinib (AS-1763) Development Incentive Stock Options (with Exercise Price Adjustment Clause)
Disclosure of the October monthly exercise status for the Docirbrutinib (AS-1763) development incentive stock options. Granted shares: 191,900 shares; number of stock acquisition rights exercised: 1,919 (after applying the exercise restriction of 0.99% of total issued); unexercised rights: 73,784 units; total issued shares during the period: 19,196,700 shares.
Key Figures
- Granted shares (shares): 191,900 shares
- Number of stock acquisition rights exercised (units): 1,919 units
- Number of unexercised stock acquisition rights: 73,784 units
AI要約
Summary of the News
Carna Biosciences, Inc. announced the monthly exercise status for October 2026 of the Docirbrutinib (AS-1763) development incentive stock options (with exercise price adjustment clause). The number of shares granted during the applicable month was 191,900 shares. The number of stock acquisition rights exercised was 1,919 units (with an exercise restriction applied equal to 0.99% of the total issued). The total unexercised stock acquisition rights amounted to 73,784 units (equivalent to 7,378,400 shares).
Impact on Shareholders and Background
The exercise ratio is rounded down at the third decimal place, and unexercised rights remain at this time. The exercise status of stock acquisition rights is influenced by the number of publicly tradable shares and the conditions of the exercise restriction; therefore, trends should be monitored in future monthly disclosures.
Carna Biosciences, Inc.
Company overview · Stock price · Financial data · All IR
